Skip to search formSkip to main contentSkip to account menu

taspoglutide

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Background and ObjectiveTaspoglutide, a glucagon-like peptide-1 agonist, like native glucagon-like peptide-1, delays gastric… 
2017
2017
To evaluate single‐dose pharmacokinetics and tolerability of taspoglutide in people with varying degrees of renal impairment and… 
Review
2015
Review
2015
To study the short‐term cardiovascular effects of the once‐weekly glucagon‐like peptide‐1 receptor agonist taspoglutide. 
2012
2012
OBJECTIVE To evaluate the efficacy and safety of taspoglutide monotherapy in drug-naive patients with type 2 diabetes… 
2012
2012
RESULTSdMean baseline HbA1c was 8.1%. Both doses of taspoglutide reduced HbA1c significantly more than exenatide (taspoglutide 10… 
2011
2011
Aim: Glucagon‐like peptide‐1 (GLP‐1) has protective effects on pancreatic β‐cells. We evaluated the effects of a novel, long… 
Highly Cited
2009
Highly Cited
2009
OBJECTIVE To evaluate the efficacy and safety of taspoglutide (R1583/BIM51077), a human once-weekly glucagon-like peptide-1… 
Review
2009
Review
2009
Background: Taspoglutide (R1583/BIM51077) is a new anti diabetic drug from Hoffmann-La Roche. The compound is to be administered… 
2009
2009
A highly sensitive liquid chromatographic method with online solid-phase extraction (SPE) and tandem mass spectrometric detection…